pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,490 catalysts · 3,350 8k filing · 577 earnings · 184 grant · 172 phase 2 completion · 133 drug shortage · 128 approval

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 0 catalysts2026-08-13: 0 catalysts2026-08-14: 66 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2026-04-07×clear all
type
  • 8k filing3,350
  • earnings577
  • grant184
  • phase 2 completion172
  • drug shortage133
  • approval128
phase 1 completion
73
  • device 510k68
  • phase 2 initiation62
  • recall52
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 27, 2026

    50
    ›Apr 30, 2026phase 2 completion107d agoOhio State University Comprehensive Cancer Center — canakinumab (Phase II Trial Completion)canakinumab

    Therapy area: Oncology. Indication: Lung Cancer

    full page →canakinumab →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoDirect Biologics LLC — DB-3Q (Phase II Trial Completion)DB-3Q

    Therapy area: Gastrointestinal. Indication: Anal Fistula, Crohn's Disease (Regional Enteritis)

    full page →DB-3Q →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoNational Cancer Institute US — ipilimumab (Phase II Trial Completion)ipilimumab

    Therapy area: Oncology. Indication: Endometrial Cancer

    full page →ipilimumab →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoBioCanRx — ipilimumab (Phase II Trial Completion)ipilimumab

    Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma

    full page →ipilimumab →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoInnovent Biologics Inc — mazdutide (Phase II Trial Completion)mazdutide

    Therapy area: Gastrointestinal. Indication: Metabolic Dysfunction-Associated Steatohepatitis (MASH or NASH)

    full page →mazdutide →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoBeijing Chao-Yang Hospital — bupivacaine liposome (Phase II Trial Completion)bupivacaine liposome

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine liposome →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoChacha Nehru Bal Chikitsalaya — Isobaric bupivacaine (Phase II Trial Completion)Isobaric bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →Isobaric bupivacaine →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoCarlo Bo University of Urbino — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Gastrointestinal. Indication: Diarrhea

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoHuzhou Maternity and Child Care Hospital — esketamine (Phase II Trial Completion)esketamine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain, Sleep Disorders

    full page →esketamine →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoJetema Co Ltd — JTM-102 (Phase II Trial Completion)JTM-102

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →JTM-102 →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoUniversity of Udine — cholecalciferol (Phase II Trial Completion)cholecalciferol

    Therapy area: Musculoskeletal Disorders. Indication: Sarcopenia

    full page →cholecalciferol →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoShionogi & Co Ltd — daridorexant hydrochloride (Phase II Trial Completion)daridorexant hydrochloride

    Therapy area: Central Nervous System. Indication: Insomnia

    full page →daridorexant hydrochloride →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoFirst Affiliated Hospital of Kunming Medical University — sugammadex (Phase II Trial Completion)sugammadex

    Therapy area: Non Malignant Disorders, Women's Health. Indication: Unspecified Gynecological Disorders, Uterine Leiomyoma (Uterine Fibroids)

    full page →sugammadex →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoInstitute of Liver and Biliary Sciences — darbepoetin alfa (Phase II Trial Completion)darbepoetin alfa

    Therapy area: Gastrointestinal. Indication: Decompensated Cirrhosis, Liver Cirrhosis

    full page →darbepoetin alfa →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

    Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

    full page →amoxicillin →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoAristotle University of Thessaloniki — oleocanthal (Phase II Trial Completion)oleocanthal

    Therapy area: Central Nervous System. Indication: Mild Cognitive Impairment

    full page →oleocanthal →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoBiogen Inc — DNL-151 (Phase II Trial Completion)DNL-151

    Therapy area: Central Nervous System. Indication: Parkinson's Disease

    full page →DNL-151 →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoAffiliated Stomatological Hospital of Guangxi Medical University — autologous platelet rich plasma (Phase II Trial Completion)autologous platelet rich plasma

    Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Arthralgia (Joint Pain), Osteoarthritis

    full page →autologous platelet rich plasma →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoVertex Pharmaceuticals Inc — VX-993 (Phase II Trial Completion)VX-993

    Therapy area: Central Nervous System. Indication: Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain

    full page →VX-993 →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoChinese Academy of Medical Sciences Plastic Surgery Hospital — recombinant type III humanized collagen (Phase II Trial Completion)recombinant type III humanized collagen

    Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)

    full page →recombinant type III humanized collagen →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoChinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)fuzuloparib

    Therapy area: Oncology. Indication: Soft Tissue Sarcoma

    full page →fuzuloparib →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoSun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)ISOTRETINOIN

    Therapy area: Oncology. Indication: Neuroblastoma

    full page →ISOTRETINOIN →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

    full page →ghrelin →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoFundacion para la Investigacion Biomedica Hospital Clinico San Carlos — cromolyn sodium (Phase II Trial Completion)Gastrocrom

    Therapy area: Central Nervous System. Indication: Multiple Sclerosis

    full page →Gastrocrom →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoGachon University Gil Medical Center — Wegovy (Phase II Trial Completion)Wegovy Pill

    Therapy area: Metabolic Disorders. Indication: Obesity

    full page →Wegovy Pill →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoWannan Medical College First Affiliated Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

    Therapy area: Undisclosed. Indication: Unspecified

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoWestern New England University — grape powder (Phase II Trial Completion)grape powder

    Therapy area: Central Nervous System. Indication: Cognitive Disorders

    full page →grape powder →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoKLE College of Pharmacy, Belagavi — undisclosed immunosuppressive drug (Phase II Trial Completion)undisclosed immunosuppressive drug

    Therapy area: Genito Urinary System. Indication: Nephrotic Syndrome

    full page →undisclosed immunosuppressive drug →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoUniversity of Minnesota — Lactobacillus casei (Phase II Trial Completion)Lactobacillus casei

    Therapy area: Musculoskeletal Disorders. Indication: Muscle Injury, Unspecified Musculoskeletal Disorders

    full page →Lactobacillus casei →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoArrae Inc — Aframomum melegueta extract (Phase II Trial Completion)Aframomum melegueta extract

    Therapy area: Metabolic Disorders. Indication: Obesity, Overweight

    full page →Aframomum melegueta extract →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

    Therapy area: Immunology. Indication: Inflammation

    full page →SSJG-009 →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoCharak Ayurvedic Pharmacy, Paprola — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Metabolic Disorders, Musculoskeletal Disorders. Indication: Hyperuricemia, Unspecified Musculoskeletal Disorders

    full page →ayurvedic medicine →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoBuddhachinaraj Hospital — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Musculoskeletal Disorders. Indication: Bone Fracture

    full page →dexamethasone →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

    Therapy area: Respiratory. Indication: Cough

    full page →LIDOCAINE →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoChongqing Medical University Hospital 2 — propofol (Phase II Trial Completion)PROPOFOL

    Therapy area: Central Nervous System. Indication: Cognitive Disorders

    full page →PROPOFOL →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoHematology Hospital of Chinese Academy of Medical Sciences — letermovir (Phase II Trial Completion)letermovir

    Therapy area: Undisclosed. Indication: Unspecified

    full page →letermovir →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoCantonal Hospital Authority — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

    full page →Vacucis →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)atezolizumab

    Therapy area: Oncology. Indication: Prostate Cancer

    full page →atezolizumab →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoNoster Inc — 10-hydroxy-cis-12- octadecenoic acid (Phase II Trial Completion)10-hydroxy-cis-12- octadecenoic acid

    Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

    full page →10-hydroxy-cis-12- octadecenoic acid →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoHospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)adebrelimab

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

    full page →adebrelimab →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)capecitabine

    Therapy area: Oncology. Indication: Colorectal Cancer

    full page →capecitabine →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoNanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)adebrelimab

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →adebrelimab →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoLifeArc — fecal microbiota (Phase II Trial Completion)fecal microbiota

    Therapy area: Gastrointestinal. Indication: Inflammatory Bowel Disease, Primary Sclerosing Cholangitis

    full page →fecal microbiota →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoNational Cheng-Kung University Hospital — SynPro-15G (Phase II Trial Completion)SynPro-15G

    Therapy area: Gastrointestinal. Indication: Irritable Bowel Syndrome

    full page →SynPro-15G →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoPolice General Hospital — acetaminophen (Phase II Trial Completion)acetaminophen ER

    Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 2 completion107d agoEmory University — (carbidopa + levodopa) (Phase II Trial Completion)(carbidopa + levodopa)

    Therapy area: Central Nervous System. Indication: Cognitive Disorders, Depression

    full page →(carbidopa + levodopa) →source: globaldata
    ›Apr 30, 20268k filing107d ago$HCWB — HCW Biologics Inc. (HCWB) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing107d ago$BCYC — BICYCLE THERAPEUTICS PLC (BCYC) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ›Apr 30, 20268k filing107d ago$RNAC — Cartesian Therapeutics, Inc. (RNAC) — 8-K filing

    Items: 2.02, 9.01

    full page →edgar 8k ↗
    ← prev
    page 26 of 90
    next →
    $SGIOF17.900.00%
    $VERX12.72-4.00%
    $BIIB209.83-0.39%
    $RCUS29.48+2.15%